58059-29-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-6-(4-chlorophenyl)-pyridazine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of novel drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-chloro-6-(4-chlorophenyl)-pyridazine is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides, due to its potential to enhance the effectiveness of these compounds in agricultural settings.
Used in Specialty Chemicals and Materials:
3-Chloro-6-(4-chlorophenyl)-pyridazine is employed as a building block in the development of specialty chemicals and materials, where its unique structural features contribute to the creation of innovative products with specific properties and applications.
Used in Organic Synthesis:
As an intermediate in organic synthesis, 3-chloro-6-(4-chlorophenyl)-pyridazine plays a significant role in the preparation of complex organic molecules, facilitating the synthesis of a wide range of compounds for various applications in research and industry.

InChI:InChI=1/C10H6Cl2N2/c11-8-3-1-7(2-4-8)9-5-6-10(12)14-13-9/h1-6H

Upstream product

• 99-91-2 para-chloroacetophenone 
• 108-90-7 chlorobenzene 
• 3984-34-7 4-(4-chlorophenyl)-4-oxobutanoic acid 
• 1079-73-8 6-(4-chlorophenyl)-4,5-dihydro-3(2H)-pyridazinone 
• 141-30-0 3,6-dichlorpyridazine 
• 274251-56-8 boronic acid 4-chlorophenyl monoester 
• 53-73-6 angiotensinamide 
• 2166-13-4 6-(p-chlorophenyl)-3(2H)-pyridazinone 
• 1679-18-1 4-Chlorophenylboronic acid 
• 89523-62-6 (4-chlorophenyl)zinc(II) chloride 

Downstream Products

• 93181-91-0 3-(4-hydroxypiperidino)-6-(4-chlorophenyl)pyridazine 
• 66548-72-9 6-(4-chloro-phenyl)-3-ethyl-[1,2,4]triazolo[4,3-b]pyridazine 
• 60478-25-3 3-(4-chloro-phenyl)-6-hydrazino-pyridazine 
• 66548-70-7 6-(4-chloro-phenyl)-[1,2,4]triazolo[4,3-b]pyridazine 
• 67972-20-7 N'-[6-(4-chloro-phenyl)-pyridazin-3-yl]-hydrazinecarboxylic acid ethyl ester 
• 66866-22-6 3-phenyl-6-(4'-chlorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1268133-93-2 3-(4'-tolyl)-6-(4'-chlorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 67820-99-9 N'-[6-(4-chloro-phenyl)-pyridazin-3-yl]-N'-(2-hydroxy-ethyl)-hydrazinecarboxylic acid ethyl ester 
• 1446019-91-5 C₂₄H₂₅ClN₄O 
• 1446021-18-6 3-(4-chlorophenyl)-6-iodopyridazine 
• 690265-67-9 3-(4-chloro-phenyl)-6-trimethylsilanylethynyl-pyridazine 
• 58059-47-5 3-amino-6-(p-chlorophenyl)pyridazine 
• 105538-26-9 6-Amino-3-(4-chloro-phenyl)-1-(3-ethoxycarbonyl-propyl)-pyridazin-1-ium; bromide 
• 93182-12-8 3-{4-[(butylcarbamoyl)oxy]piperidino}-6-(4-chlorophenyl)pyridazine 

Relevant academic research and scientific papers

Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]triazolo[4,3-b] Pyridazines as Antitubulin Agents

A series of 3,6-diaryl-[1,2,4]triazolo[4,3-b]pyridazines were designed as a class of vinylogous CA-4 analogues. The easily isomerized (Z,E)-butadiene linker of vinylogous CA-4 was replaced by a rigid [1,2,4]triazolo[4,3-b]pyridazine scaffold. Twenty-one target compounds were synthesized and exhibited moderate to potent antiproliferative activity. The compound 4q with a 3-amino-4-methoxyphenyl moiety as the B-ring, comparable to CA-4 (IC50 = 0.009-0.012 μM), displayed the highly active antiproliferative activity against SGC-7901, A549, and HT-1080 cell lines with IC50 values of 0.014, 0.008, and 0.012 μM, respectively. Tubulin polymerization experiments indicated that 4q effectively inhibited tubulin polymerization, and immunostaining assay revealed that 4q significantly disrupted tubulin microtubule dynamics. Moreover, cell cycle studies revealed that compound 4q dramatically arrested cell cycle progression at G2/M phase in A549 cells. Molecular modeling studies showed that 4q could bind to the colchicine binding site on microtubules.

Synthesis, vasorelaxant activity and 2D-QSAR study of some novel pyridazine derivatives

Novel 3,6-disubstituted pyridazines were synthesized by facile method and screened for their vasorelaxant properties utilizing isolated thoracic rat aortic rings. Compounds 8a and 11a exerted potent vasorelaxant activity (IC50 = 198 and 177 μM, respectively) relative to doxazosin mesylate (used reference standard, IC50 = 226 μM), that, they may represent promising hits for treatment of cardiovascular disorders. The observed activity was validated by a statistically significant QSAR model (N = 32, n = 6, R2 = 0.811782, R2cvOO = 0.7153, R2cvMO = 0.7209, F = 17.9708, s2 = 9.65226 × 10-8) that was obtained employing CODESSA-Pro software.

Highly selective mono-substitution in Pd-catalyzed cross-coupling reactions of 3,6-dichloropyridazine with organozinc compounds

Pd-catalyzed cross-coupling reactions of 3,6-dichloropyridazine (1) with benzyl, aryl, and alkyl organozinc compounds led to selective mono-substitution of one of the chlorine atoms. The subsequent cross-coupling of the resulting monochlorides with RZnCl afforded unsymmetrical 3,6-carbon-disubstituted pyridazines.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings as cited in Claim 1. The invention also relates to medicaments containing at least one inventive alkyne. The MCH receptor antagonistic effect renders the inventive medicaments suitable for treating metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.

Synthesis and Structure-Activity Relationships of Series of Aminopyridazine Derivatives of γ-Aminobutyric Acid Acting as Selective GABA-A Antagonists

We have recently shown that an aryloaminopyridazine derivarive of GABA, SR 95103 , is a selective and competitive GABA-A receptor antagonist.In order to further explore the structural requirements for GABA receptor affinity, we synthesized a series of 38 compounds by attaching various pyridazinic structures to GABA or GABA-like side chains.Most of the compounds displaced GABA from rat brain membranes.All the active compounds antagonized the GABA-elicited enhancement of diazepam binding, strongly suggesting that all these compounds are GABA-A receptor antagonists.None of the compounds that displaced GABA from rat brain membranes interacted with other GABA recognition sites (GABA-B receptor, GABA uptake binding site, glutamate decarboxylase, GABA-transaminase).They did not interact with the Cl- ionophore associated with the GABA-A receptor and did not interact with the benzodiazepine, strychnine, and glutamate binding sites.Thus these compounds appear to be specific GABA-A receptor antagonists.In terms of structure-activity, it can be concluded that a GABA moiety bearing a positive charge is necessary for optimal GABA-A receptor recognition.Additional binding sites are tolerated only if they are part of a charge-delocalized amidinic or guanidinic system.If this delocalization is achieved by linking a butyric acid moiety to the N(2) nitrogen of a 3-aminopyridazine, GABA-antagonistic character is produced.The highest potency (ca.250 times bicuculline) was observed when an aromatic ? system, bearing electron-donating substituents, was present on the 6-position of the pyridazine ring.

CHLOROSULFONYL ISOCYANATE:AN UNUSUAL CHLORINATING AGENT

The reaction of chlorosulfonyl isocyanate with 6-aryl-3(2H)pyridazinones yields unusually 3-chlorosubstituted pyridazines.

Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates

This disclosure describes novel alkyl 3-[6-(aryl)-3-pyridazinyl]-carbazates useful as hypotensive agents in mammals. SP CROSS REFERENCE TO RELATED APPLICATIONS This application is a continuation of our copending application Ser. No. 692,254, filed June 3, 1976 now abandoned, which in turn is a continuation-in-part of our abandoned application Ser. No. 552,024, filed Feb. 24, 1975 now abandoned.

Method for treating anxiety in mammals

This disclosure describes compositions of matter useful as anxiolytic agents and the method of meliorating anxiety in mammals therewith; the active ingredients of said compositions of matter being certain substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines or the pharmacologically acceptable acid-addition salts thereof.